Multiple ubiquitin ligases protect human genome integrity by targeting cancer-associated APOBEC3 deaminases for degradation

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Members of the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) family play crucial roles as antiviral restriction factors, yet some APOBEC3 (A3) members drive harmful hypermutation in humans, contributing to cancer. The cancer-associated A3 proteins are capable to transit from the cytosol to nucleus, driving genome mutations. Here, we show that the major cancer-associated members are efficiently removed by the ubiquitin-proteasome pathway, pointing to distinct cellular pathways protecting genomic DNA from hypermutation. Through genetic and proteomic screening UBR4, UBR5, and HUWE1 were identified as the ubiquitin E3 ligases marking cancer-associated A3B and A3H-I for degradation, thereby limiting A3-driven hypermutation. Mechanistically, UBR5 and HUWE1 recognize the unoccupied A3 RNA-binding domain, promoting proteasomal degradation. Depletion or mutation of the E3 ligases in cell models and cancer samples increased A3-driven genome mutagenesis. Our findings reveal UBR4, UBR5, and HUWE1 as crucial factors of a ubiquitination cascade maintaining human genome stability.

Highlights

  • When not bound to RNA, APOBEC3 proteins enter the nucleus, driving genome mutations.

  • UBR4, UBR5, and HUWE1 mark cancer-associated deaminases A3B and A3H-I for proteasomal degradation.

  • The E3 ligases target the RNA-binding domain of A3s in their uncomplexed state.

  • A distinct ubiquitination pathway protects genomic DNA from A3-mediated mutagenesis.

Article activity feed